about
Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-AnalysisLate tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literatureAnthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.Paraneoplastic cerebellar degeneration associated with ovarian cancerPharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated riskWeekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancerPrognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
P50
Q26785421-32A78998-0BA1-4201-B3D4-530A5E34E43AQ33578242-66717629-3E9D-4505-A715-B9BB3D25C389Q33629632-D215B58A-EF4D-4427-B6B3-E142BB60EECFQ34996054-A399D424-228B-4566-9992-E1FDDC644F91Q35789363-D596CF8C-CFA7-44C7-901D-84C82ACD58D7Q36611469-205F5C6C-1D0E-41A7-B024-474F2D24A3C6Q37457684-3DAF0C2F-9F5C-44A2-B823-291909544EC6Q40811026-058E263F-66BE-4F3A-B445-AE455843AC5DQ41421332-78184E7C-656B-4C71-A1CB-2435C8E5D027Q42947465-073D4476-9974-4B66-B719-3C547DB78DCFQ44056096-DEF93571-C290-42C1-8E1B-25E38605A161Q55259197-0DBFA628-2D77-4870-8F3E-B7818E4929D2Q60697869-95D325E9-CAD8-47DE-8194-8556C0B3FC6CQ84514196-D5E0BFC5-CF2E-4C47-A8F5-B57CF2F280DEQ91230219-23DA0678-EF86-489A-A6D0-8990358B5903Q91566007-3B56A91D-2F77-4432-BB14-F15994C55039
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Simona Scalone
@en
Simona Scalone
@nl
type
label
Simona Scalone
@en
Simona Scalone
@nl
prefLabel
Simona Scalone
@en
Simona Scalone
@nl
P31
P496
0000-0002-4647-0919